|
| 37085425 | Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. | Eur Urol | 2024 |
| 37951974 | Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. | Br J Cancer | 2024 |
| 37963304 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial. | J Clin Oncol | 2024 |
| 36913920 | Predictors of Mortality among Patients Hospitalized with COVID-19 during the First Wave in India: A Multisite Case-Control Study. | | 2023 |
| 36043882 | Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 |
| 35835693 | Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. | European Urology Focus | 2023 |
| 36272943 | Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. | Eur Urol | 2023 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 36318705 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 |
| 38039002 | Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. | JAMA Netw Open | 2023 |
| 37672815 | The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. | Eur J Cancer | 2023 |
| 37597001 | Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches. | | 2023 |
| 37903742 | Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. | | 2023 |
| 37644774 | Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer. | | 2023 |
| 37882449 | TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. | | 2023 |
| 37708629 | Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. | Eur J Cancer | 2023 |
| 37966506 | A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. | World J Urol | 2023 |
| 37620429 | Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. | | 2023 |
| 38049622 | First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | | 2023 |
| 37958345 | Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. | | 2023 |
| 37477913 | Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. | Clin Cancer Res | 2023 |
| 37414620 | Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. | Clin Genitourin Cancer | 2023 |
| 37347470 | Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma. | | 2023 |
| 37285865 | Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 36509613 | Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. | | 2023 |
| 36952231 | Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. | | 2023 |
| 36573926 | Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. | J Urol | 2023 |
| 37460732 | Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. | | 2023 |
| 37014098 | The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice. | | 2023 |
| 36948922 | Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 36484444 | Editorial Comment. | | 2023 |
| 36481176 | Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2023 |
| 37322621 | Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. | Asian J Androl | 2023 |
| 37442702 | Advances in the treatment of metastatic prostate cancer. | | 2023 |
| 37062953 | Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. | | 2023 |
| 37248148 | Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. | | 2023 |
| 36621463 | Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis. | | 2023 |
| 37304495 | Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study. | EClinicalMedicine | 2023 |
| 37046747 | High-Risk Pedigree Study Identifies (rs62346982) as a Likely Predisposition Variant for Prostate Cancer. | | 2023 |
| 36795308 | Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. | Curr Cardiol Rep | 2023 |
| 36789668 | The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer. | | 2023 |
| 37526936 | Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. | JAMA Netw Open | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37509379 | Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. | | 2023 |
| 37495481 | Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. | | 2023 |
| 37220335 | Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. | Am Soc Clin Oncol Educ Book | 2023 |
| 34473525 | Recent Advances in the Management of Metastatic Prostate Cancer. | JCO Oncology Practice | 2022 |
| 36048457 | Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. | JAMA Oncology | 2022 |
| 36177428 | Financial literacy and its correlates among healthcare professionals of India: An ignored educational need. | Journal of Education and Health Promotion | 2022 |
| 36097192 | ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. | Oncogene | 2022 |